Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/12/2025 | $28.00 | Buy | B. Riley Securities |
| 8/6/2024 | $15.00 → $10.00 | Outperform → Market Perform | Leerink Partners |
| 4/12/2024 | $21.00 | Buy | BTIG Research |
| 1/8/2024 | Outperform → In-line | Evercore ISI | |
| 5/23/2022 | $12.00 | Outperform | SVB Leerink |
| 3/2/2022 | $10.00 → $11.00 | Underweight | Morgan Stanley |
| 2/24/2022 | $8.00 → $12.00 | Buy | HC Wainwright & Co. |
| 11/5/2021 | $7.00 → $12.00 | Underweight → Neutral | JP Morgan |
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
Ampreloxetine clinical development program to be featured in four presentations at the upcoming International Symposium on The Autonomic Nervous SystemTopline results from the ongoing Phase 3 CYPRESS study of ampreloxetine anticipated in Q1 2026DUBLIN, Oct. 29, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that it will be participating at the 36th International Symposium on the Autonomic Nervous System, organized by the American Autonomic Society (AAS), taking place November 5-8, 2025, in Clearwater Beach, FL. The Company will have one platform presentation and three poster presentations on its clinical development program for ampreloxetine, a potential first-
DUBLIN, Oct. 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST / 10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in the live audio webcast of the conference call may access it by clicking here or visiting the Events and Presentation page unde
Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced the launch of "Power in the Periphery," a new disease education campaign for healthcare professionals (HCPs) to raise awareness and deepen scientific understanding of the pathophysiology underlying neurogenic orthostatic hypotension (nOH) associated with Multiple System Atrophy (MSA). The initiative was introduced at the International Congress of Parkinson's Disease and Movement Disorders® (MDS), held in Honolulu, Hawaii, October 5–9, 2025. "The 'Power in the Periphery' campaign underscores our ongoing commitment to advancing education for healthcare professionals about the complex mechanisms underlying nOH," said Rick E Winningham,
B. Riley Securities initiated coverage of Theravance Biopharma with a rating of Buy and set a new price target of $28.00
Leerink Partners downgraded Theravance Biopharma from Outperform to Market Perform and set a new price target of $10.00 from $15.00 previously
BTIG Research initiated coverage of Theravance Biopharma with a rating of Buy and set a new price target of $21.00
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
10-Q - Theravance Biopharma, Inc. (0001583107) (Filer)
Enters into Cooperation Agreement with Shareholder Irenic Capital Reaffirms Intention to Return All Excess Capital to Shareholders and MaximizeShareholder Value DUBLIN, Dec. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ:TBPH) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special Advisor to Irenic Capital Management LP ("Irenic"). With the addition of Mr. Grant, Theravance has appointed four new directors to the Board since 2020. "We are pleased to welcome Jeremy to the Theravance Board a
Believes Jim Kelly of Weiss Asset Management Will Bring Important Ownership Mentality to the Boardroom Encourages the Board to Continue Taking Concrete Steps to Improve Capital Allocation, Enhance Corporate Governance and Review Strategic Alternatives Irenic Capital Management, LP (together with its affiliates, "Irenic" or "we"), a top shareholder of Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance" or the "Company"), today issued the following statement regarding the Company's appointment of Jim Kelly, Managing Director at Weiss Asset Management, to the Board of Directors (the "Board"): "Irenic welcomes the appointment of Jim Kelly to the Theravance Board. We respect and admire
DUBLIN, April 11, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced the appointment of Jim Kelly, Managing Director at Weiss Asset Management, the Company's second largest shareholder, to its Board of Directors. With the appointment of Mr. Kelly, four new directors have joined the Company's Board of Directors since 2018 as part of its ongoing board refreshment process. "We are pleased to welcome Jim Kelly to the Theravance Board of Directors. Weiss Asset Management has been one of our largest shareholders si
Ampreloxetine clinical development program to be featured in four presentations at the upcoming International Symposium on The Autonomic Nervous SystemTopline results from the ongoing Phase 3 CYPRESS study of ampreloxetine anticipated in Q1 2026DUBLIN, Oct. 29, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that it will be participating at the 36th International Symposium on the Autonomic Nervous System, organized by the American Autonomic Society (AAS), taking place November 5-8, 2025, in Clearwater Beach, FL. The Company will have one platform presentation and three poster presentations on its clinical development program for ampreloxetine, a potential first-
DUBLIN, Oct. 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST / 10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in the live audio webcast of the conference call may access it by clicking here or visiting the Events and Presentation page unde
Topline results anticipated in Q1 2026 and, if successful, planning for expedited NDA submission If approved, ampreloxetine could address a critical unmet need as the first therapy with the potential to provide durable benefit for the 40,000 patients in the U.S. with symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)Ampreloxetine has Orphan Drug Designation in the U.S., underscoring the unmet need in symptomatic nOH due to MSADUBLIN, Aug. 25, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH), today announced completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS s
SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)
SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)
SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)